ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Exelixis, a South San Francisco-based small-molecule biotech firm, is eliminating 70% of its workforce following disappointing results in a Phase III clinical trial of cabozantinib, its thyroid cancer drug, for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The job cuts will bring total employment to 70.
The news is the latest in a string of disappointments for the chemistry-based company, which in 2010 reduced its staff by 40%, eliminating 270 jobs, in an effort to narrow its once-broad focus on multiple cancer compounds.
Exelixis says the new job cuts, which hit employees involved with the mCRPC trials, will enable it to devote financial resources to late-stage trials of cabozantinib in metastatic renal cell carcinoma and advanced hepatocellular carcinoma.
Exelixis, which posted revenues of $31.3 million in 2013, down from $152 million in 2009, anticipates a one-time restructuring fee of up to $8 million as a result of the workforce reduction. The firm’s sales currently come from cabozantinib marketed as Cometriq for the treatment of metastatic medullary thyroid cancer, a rare disease.
At its prime, Exelixis had more than 300 research-related employees, a library of 4.5 million compounds that yielded 15 candidates deemed worthy of clinical trials, and partnerships with six large drug firms. Now its future hinges on a handful of clinical trials testing other indications for cabozantinib.
“From a balance sheet perspective they are in dire straits,” says Biren Amin, an analyst at Jefferies. The company has $349 million in debt and $352 million in cash, “but they are burning through that cash. Both trials require significant investment.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter